Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:16:27.069Z.
Calculation as of: 2026-10-06T15:16:27.069Z.
Quote observation: 2026-10-06T15:15:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3328ed161ff00c537a80d7dceb604f662f1c22c4e65cb57a824bf36ce3bbbe60
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Corvus Pharmaceuticals, Inc.
Market Cap
$881.97M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$902.67M
Price/OCF Ratio
N/A
TTM Avg
1973.56
3Y Avg
1192.17
5Y Avg
1192.17
Market Cap
$860.85M
Price/OCF Ratio
N/A
TTM Avg
10.75
3Y Avg
10.75
5Y Avg
10.75
Market Cap
$914.44M
Price/OCF Ratio
12.74
TTM Avg
11.45
3Y Avg
13.28
5Y Avg
14.23
Market Cap
$838.66M
Price/OCF Ratio
N/A
TTM Avg
185.06
3Y Avg
185.06
5Y Avg
185.06
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $881.97M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $891.90M | 9.21 | 9.21 | 23.47 | 25.52 |
| Arbutus Biopharma Corp (ABUS)vs › | $902.67M | N/A | 1973.56 | 1192.17 | 1192.17 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $860.85M | N/A | 10.75 | 10.75 | 10.75 |
| HealthStream, Inc. (HSTM)vs › | $914.44M | 12.74 | 11.45 | 13.28 | 14.23 |
| CeriBell, Inc. (CBLL)vs › | $928.24M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.66M | N/A | 185.06 | 185.06 | 185.06 |
| Alumis Inc. (ALMS)vs › | $839.24M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $841.31M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $833.81M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
